Sempatomimetik İlaç Zehirlenmeleri

Yazarlar

Semih Eriten

Özet

Sempatomimetik ilaçlar, adrenerjik, dopaminerjik ve serotonerjik reseptörleri etkileyerek sempatik sinir sistemini uyaran endojen nörotransmiterlerin hareketlerini taklit eden maddelerdir. Bu grupta kokain, amfetamin, metamfetamin, MDMA ve MDA gibi tasarım amfetaminlerin yanı sıra kafein ve teofilin gibi bileşikler yer almaktadır. Kötüye kullanımı ve yasa dışı tüketimi oldukça yaygın olan bu maddelerle meydana gelen zehirlenmelerde hastalar acil servise merkezi sinir sistemi, kardiyovasküler, solunum ve kas sistemlerini etkileyen ağır klinik tablolarla başvururlar. Karakteristik toksidrom belirti ve bulguları arasında sinüs taşikardisi, hipertansiyon, hipertermi, anksiyete, ajitasyon, midriyazis, nöbetler, miyokard iskemisi veya enfarktüsü, terleme, metabolik asidoz, yüksek kas enzimleri ve rabdomiyoliz bulunmaktadır. Tedavi yaklaşımında temel ilke hastayı hipoksi ile kardiyak iskemiden korumak ve vital fonksiyonları stabilize etmektir; kardiyak izlem, intravenöz sıvı desteği, oksijen tedavisi, sedasyon ve hipertansiyon kontrolü amacıyla benzodiazepinler, nitrogliserin ve kalsiyum kanal blokerleri tercih edilmektedir. İlaç yutulması veya vücut paketçiliği vakalarında aktif kömür ve tüm bağırsak yıkaması gibi gastrointestinal dekontaminasyon teknikleri uygulanırken, şiddetli hipertermide hızlı soğutma yöntemleri devreye sokulur. Tanısal değerlendirmede kanda ölçülen ilaç seviyeleri toksisitenin klinik şiddetiyle doğrudan korelasyon göstermediğinden nicel kan düzeyleri yerine nitel idrar uyuşturucu taramaları kullanılır; ancak amfetamin taramalarında görülebilen yanlış pozitif sonuçlar nedeniyle doğrulayıcı kromatografik laboratuvar analizlerine ihtiyaç duyulmaktadır.

Sympathomimetic drugs are substances that mimic the actions of endogenous neurotransmitters that stimulate the sympathetic nervous system by affecting adrenergic, dopaminergic, and serotonergic receptors. This group includes cocaine, amphetamine, methamphetamine, designer amphetamines such as MDMA and MDA, as well as compounds like caffeine and theophylline. In poisonings involving these substances, whose abuse and illicit consumption are quite common, patients present to the emergency department with severe clinical conditions affecting the central nervous system, cardiovascular, respiratory, and musculoskeletal systems. Characteristic toxidrome signs and symptoms include sinus tachycardia, hypertension, hyperthermia, anxiety, agitation, mydriasis, seizures, myocardial ischemia or infarction, diaphoresis, metabolic acidosis, elevated muscle enzymes, and rhabdomyolysis. The fundamental principle in therapeutic management is to protect the patient from hypoxia and cardiac ischemia and to stabilize vital functions; cardiac monitoring, intravenous fluid support, oxygen therapy, and medications such as benzodiazepines, nitroglycerin, and calcium channel blockers for sedation and blood pressure control are preferred in first-line treatment. While gastrointestinal decontamination techniques such as activated charcoal and whole bowel irrigation are applied in drug ingestion or body packer cases, rapid cooling methods are implemented for severe hyperthermia. In diagnostic evaluation, qualitative urine drug screens are utilized instead of quantitative blood levels, as measured blood drug levels do not correlate directly with the clinical severity of toxicity; however, confirmatory chromatographic laboratory analyses are required due to false-positive results that can occur in amphetamine screenings.

Referanslar

Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol. 1993;32: 639-677.

Hoffman BB, Lefkowitz RJ. (1996).Catecholamines, sympath- omimetic drugs, and adrenergic receptor antagonists. In J.G. Hardman, L.Ê. Limbird, & P.B. Molinoff et al (Eds.), Goodman and Gilman’s the pharmacological basis of therapeutics (9th ed., pp. 199-227). New York, NY: McGraw-Hill.

Williams RH, Erickson T, Broussard LA. Evaluating sympathomimetic intoxication in an emergency setting. Laboratory Medicine. 2000: 31(9):497-508.

Shannon M. Clinical toxicity of cocaine adulterants. Ann Emerg Med. 1988;17:1243-1247.

Stewart DJ, Inaba T, Lucassen M, et al. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther. 1979;25:464-468.

Isenschmid DS. (1999).Cocaine. In B. Levine (Ed.), Principles of Forensic Toxicology (pp. 221-245).Washington, DC: AACC Press.

Brookoff D, Rotondo MF, Shaw LM, et al. Cocaethylene levels in patients who test positive for cocaine. Ann Emerg Med. 1996;27:316-320.

Henning RJ, Wilson LD, Glauser JM. Cocaine plus ethanol is more car- diotoxic than cocaine or ethanol alone. Crit Care Med. 1994;22:1896-1906.

Weis RD, Gawin FH. Protracted elimination of cocaine metabolites in long-term high dose cocaine abuse. Am J Med. 1988;85:879-880.

Hollander JE. Management of cocaine-associated myocardial ischemia.N Engl J Med. 1995;333:1267-1272.

Hollander JE, Hoffman RS. (1998). Cocaine. In L.R. Goldfrank, N.E. Flomenbaum, N.A. Lewin (Eds), Goldfrank’s Toxicologic Emergencies (6th Ed., pp.1071-1089) Stamford, CT: Appleton & Lange.

Gitter MJ, Goldsmith ER, Dunbar DN, et al. Cocaine and chest pain: clinical features and outcome of patients hospitalized to rule out myocardial infarction. Ann Intern Med. 1991;115:277-282.

Glennon RA. Stimulation properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationship. NIDA Res Monogr. 1989;94:43-67.

Battaglia G, DeSouza EB. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr. 1989;94:240-248.

Moore K. (1999). Amphetamines/sympathomimetic amines. In B. Levine (Ed.), Principles of Forensic Toxicology (pp. 265-284). Washington, DC: AACC Press.

Blum K. (1984). Central nervous system stimulants. In K. Blum (Ed.), Handbook of Arousable Drugs (pp. 305-347). New York, NY: Gardner.

Greenblatt JC, Gfroerer JC, Melnick D. Increasing morbid- ity and mortality associated with abuse of methamphetamine United States, 1991-1994. MMWR Morb Mortal Wkly Rep. 1995;44:882-886.

Chiang WK, Goldfrank LR: Substance withdrawal. Emerg Med Clin North Am. 1990;8:613-631.

Nichols DE, Oberlender R. Structure-activity relationships of MDMA-like substances. NIDA Res Monogr. 1989;94:1-29.

Randall T. Ecstasy-fueled “rave” parties become dances of death for English youths. JAMA. 1992;268:1505-1506.

Randall T. “Rave” scene, ecstasy use, leap Atlantic.JAMA. 1992;268:1506.

De Souza EB, Battaglia G. Effects of MDMA and DA on brain serotonin neurons: evidence from neurochemical and autoradiographic studies. NIDA Res Monogr. 1989;94:196-222.

Simpson DL, Rumack BH. Methylenedioxymethamphetamine: clinical description of overdose, death, and review of pharmacology. Arch Intern Med. 1981;141:1507-1509.

Kalix P. Pharmacological properties of the stimulant khat. Pharmacol Ther. 1990;48:397-416.

Chiang WK. Amphetamines. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al. Goldfrank’s Toxicologic Emergencie.s 6th ed. Stamford, CT: Appleton & Lange; 1998:1091-1103.

Kendrick WC, Hull AR, Knochel JP. Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med. 1977;86:381-387.

Hoffman RS, Hollander JE. Thrombolytic therapy in cocaine-induced myocardial infarction. Am J Emerg Med. 1996;14:693-695.

İndir

Yayınlanan

6 Nisan 2021

Lisans

Lisans